CWHM-1552 (oral; 3-30 mg / kg / day for 4 days) inhibited 99.9% of parasitic diseases at 30 mg / kg / day and 94% of parasitic diseases at 10 mg / kg / day. CWHM-1552 (i.v. administration; 2 mg / kg / day for 48 hours) has a considerable half-life (2.7 h) and low clearance in mice. CWHM-1552 has good pharmacokinetic properties and oral efficacy in a mouse model of malaria. The ED90 of CWHM-1552 in vivo was<10 mg / kg / day and ED99 was 30 mg / kg / day respectively.

CWHM-1552 is an effective oral inhibitor of Plasmodium falciparum. For the 3D7 and Dd2 strains, the IC50 is 51 nM and 53 nM, respectively.

CWHM-1552 (oral; 3-30 mg / kg / day for 4 days) inhibited 99.9% of parasitic diseases at 30 mg / kg / day and 94% of parasitic diseases at 10 mg / kg / day. CWHM-1552 (i.v. administration; 2 mg / kg / day for 48 hours) has a considerable half-life (2.7 h) and low clearance in mice. CWHM-1552 has good pharmacokinetic properties and oral efficacy in a mouse model of malaria. The ED90 of CWHM-1552 in vivo was<10 mg >

2368253-58-9

C22H27F2N3O

387.47

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years